Hero

Celyad Announces Third Quarter 2017 Business Update

1

Celyad Announces Third Quarter 2017 Business Update

Celyad reports a first complete response in a relapsed refractory AML patient in the THINK trial

2

Celyad reports a first complete response in a relapsed refractory AML patient in the THINK trial

Celyad announces new agreements with Celdara Medical and Dartmouth College

3

Celyad announces new agreements with Celdara Medical and Dartmouth College

Celyad reports promising early results at first dose level of the solid arm of the THINK trial

4

Celyad reports promising early results at first dose level of the solid arm of the THINK trial

Celyad grants to Novartis a non-exclusive license for its allogeneic TCR-deficient CAR-T cells patents

5

Celyad grants to Novartis a non-exclusive license for its allogeneic TCR-deficient CAR-T cells patents

About Celyad

Making the Impossible Possible

Celyad is a clinical-stage biopharmaceutical that is developing next generation CAR-T NK cell-based immunotherapies for cancer treatment.

More info about Celyad

Latest News

Celyad Announces Third Quarter 2017 Business Update

Celyad Announces Third Quarter 2017 Business Update

Conference call - Update on Clinical Strategy

Conference call - Update on Clinical Strategy

Celyad reports a first complete response in a relapsed refractory AML patient in the THINK trial

Celyad reports a first complete response in a relapsed refractory AML patient in the THINK trial

Discover all news

Carousel

Social Feed